Ideaya Biosciences announced selection of a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous non-small cell lung cancer, or NSCLC, based on adverse event profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1.1.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences announces inducement grants under Nasdaq listing rule
- TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
- Ideaya Biosciences participates in a conference call with JPMorgan
- Ideaya Biosciences price target raised to $60 from $40 at Citi
- Ideaya enters supply agreement with Merck to evaluate IDE161, Keytruda
